Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Drugs And Biologics Approved By US FDA In 2016

Executive Summary

FDA's Center for Drug Evaluation and Research cleared 22 novel agents in 2016, and the Center for Biologics Evaluation and Research approved six new biologic products.

You may also be interested in...



Internal US FDA Disagreements Feature In One-Quarter Of Novel Approvals

A team led by Dalhousie University researchers examined 174 novel approvals from 2011-2015 and found 155 instances of disagreement, affecting 42 drugs.

Keeping Track: Veklury NDA Arrives At US FDA; Olinvyk Sees Approval; MAb Filings By Regneron, Y-mAbs

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep

The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel